Skip to main content
SpringerLink
Log in

Antidementia Drugs

  • Chapter
  • First Online:
Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents

  • 2644 Accesses

Abstract

Alzheimer’s disease (AD) is the most commonly occurring dementia and consists of both cognitive impairment and behavioral disturbances. Two types of medication classes are approved by the regulatory agencies for AD treatment. The cholinesterase inhibitors (ChEIs) are used for patients with mild, moderate, and severe AD. Memantine (MEM) is indicated for moderate to severe AD patients. ChEIs and MEM are often combined together for treatment. The pharmacokinetics (PK) of the ChEIs is well known. Donepezil and galantamine display linear PK, whereas rivastigmine has nonlinear PK. Donepezil and galantamine are metabolized by the CYP2D6 and CYP3A4 enzymes. Rivastigmine is metabolized by the hepatic esterases. MEM is not significantly metabolized by the hepatic enzymes and is primarily excreted by the kidneys. Dosage adjustments are recommended for patients with severe hepatic and renal impairment. The clinical pharmacodynamic (PD) properties for the ChEIs and MEM can be assessed by various biomarkers that include cholinesterase enzyme inhibition, clinical rating scales for cognitive impairment and behavioral symptoms, and PET scan evaluations. Pharmacogenetic status is in its early utilization phase of clinical utility in AD patients. PET scans may provide useful information on patient response to ChEIs and MEM. The gastrointestinal adverse side effects limit ChEIs, but these effects are transient and associated with dose titration. Population PK analysis can integrate the PK, PD, and pharmacogenetic data to optimize treatment in patients with AD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Slattum PW, Peron EP, Hill AM (2014) Alzheimer’s disease. In: DiPiro JT, Talbert RL, Yee GC et al (eds) Pharmacotherapy: a pathophysiologic approach, 9th edn. McGraw-Hill, New York, pp 817–833

    Google Scholar 

  2. Steele CD, Steinberg M, Milles G, Jann MW (1999) Recognition and management of early Alzheimer’s disease. JCOM 6:52–67

    Google Scholar 

  3. Seltzer B (2007) Donepezil: an update. Expert Opin Pharmacother 8:1011–1023

    Article  CAS  PubMed  Google Scholar 

  4. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2000) Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 48:391–395

    Article  CAS  PubMed  Google Scholar 

  5. Jann MW, Small GW (2009) Cholinesterase inhibitors and similarly acting compounds. Chapter 31.15. In: Sadock BJ, Sadock VA, Ruiz R (eds) Comprehensive textbook of psychiatry, 9th edn. Lippincott, Williams, and Wilkens, Philadelphia, PA, pp. 3089–3099

    Google Scholar 

  6. Noetzli M, Eap CB (2013) Pharmacodynamic, pharmacokinetic, and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet 52:225–251

    Article  CAS  PubMed  Google Scholar 

  7. Jann MW (1998) Pharmacology and clinical efficacy of cholinesterase inhibitors. Am J Health Syst Pharm 55(Suppl 2):S22–S25

    CAS  PubMed  Google Scholar 

  8. Jann MW, Grossberg G (2000) Cholinesterase inhibitors in the treatment of Alzheimer’s disease. Consult Pharm 15(Suppl B):7–15

    Google Scholar 

  9. Mihara M, Ohnishi A, Tomono Y et al (1993) Pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 31(5):223–229

    CAS  PubMed  Google Scholar 

  10. Rogers SL, Friedhoff LT (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 46(Suppl 1):1–6

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Eisai (2014) ARICEPT® (donepezil hydrochloride) tablets: prescribing information. Eisai Inc., Woodcliff Lake, NJ

    Google Scholar 

  12. FDA (2010) Application number: 022568. Center for Drug Evaluation and Research; Clinical Pharmacology and Biopharmaceutics Review(s)

    Google Scholar 

  13. Rogers C, Sukovaty P, Lee F (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 46(S1):7–12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tiseo PJ, Perdomo CA, Friedhoff LT (1998) Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 46(Suppl 1):19–24

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Ohnishi A, Mihara M, Kamakura H et al (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 33:1086–1091

    Article  CAS  PubMed  Google Scholar 

  16. Haywood WM, Mukaetova-Ladinska EB (2006) Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer’s disease. Am J Geriatr Pharmacother 4:273–286

    Article  CAS  PubMed  Google Scholar 

  17. Griffith P, Lichtenberg P, Goldman R, Payne-Parrish J (2006) Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer’s disease. J Natl Med Assoc 98:1590–1597

    PubMed  PubMed Central  Google Scholar 

  18. Nagy CF, Kumar D, Cullen EI et al (2004) Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clini Pharmacol 58(Suppl 1):18–24

    Article  CAS  Google Scholar 

  19. Reyes JF, Vargas R, Kumar D, Cullen EI, Perdomo CA, Pratt RD (2004) Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. Br J Clin Pharmacol 58(Suppl 1):9–17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Nordberg A, Svensson A-L (1998) Cholinesterase inhibitors in the treatment of Alzheimer’s disease. Drug Saf 19:465–480

    Article  CAS  PubMed  Google Scholar 

  21. Jann MW, Shirley KL, Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41:719–739

    Article  CAS  PubMed  Google Scholar 

  22. Polinsky RJ (1998) Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther 20:634–647

    Article  CAS  PubMed  Google Scholar 

  23. Anand R, Gharabawi G, Enz A (1996) Efficacy and safety results of the early phase studies with Exelon (TM)(ENA-713) in Alzheimer’s disease: an overview. J Drug Dev Clin Pract 8:109–116

    CAS  Google Scholar 

  24. Novartis (2015) Exelon® Patch (rivastigmine transdermal system), full prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Google Scholar 

  25. Kennedy JS, Polinsky RJ, Johnson B et al (1999) Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 19:513–521

    Article  CAS  PubMed  Google Scholar 

  26. Spencer CM, Noble S (1998) Rivastigmine. A review of its use in Alzheimer’s disease. Drugs Aging 13:391–411

    Article  CAS  PubMed  Google Scholar 

  27. Williams BR, Nazarians A, Gill MA (2003) A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther 25:1634–1653

    Article  CAS  PubMed  Google Scholar 

  28. Cutler NR, Polinsky RJ, Sramek JJ et al (1998) Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease. Acta Neurol Scand 97:244–250

    Article  CAS  PubMed  Google Scholar 

  29. Krall WJ, Sramek JJ, Cutler NR (1999) Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 33:441–450

    Article  CAS  PubMed  Google Scholar 

  30. Janssen (2013) RAZADYNE® ER (galantamine hydrobromide) full prescribing information. Janssen Pharmaceuticals, Inc., Titusville, NJ

    Google Scholar 

  31. Farlow MR (2003) Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 42:1383–1392

    Article  CAS  PubMed  Google Scholar 

  32. VanDenBerg CM, Kazmi Y, Jann MW (2000) Cholinesterase inhibitors for the treatment of Alzheimer’s disease in the elderly. Drugs Aging 16:123–138

    Article  CAS  PubMed  Google Scholar 

  33. Zhao Q, Iyer GR, Verhaeghe T et al (2002) Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. J Clin Pharmacol 42:428–436

    Article  CAS  PubMed  Google Scholar 

  34. Gomolin JH, Smith C, Jeitner TM (2011) Cholinesterase inhibitors: applying pharmacokinetics to clinical decision making. Am J Geriatr Pharmacother 9:259–263

    Article  CAS  PubMed  Google Scholar 

  35. Noetzli M, Guidi M, Ebbing K et al (2014) Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR, NR1/2 genotypes on donepezil clearance. Br J Clin Pharamacol 78:135–144

    Article  CAS  Google Scholar 

  36. Piotrovsky V, Van Peer A, Van Osselaer N et al (2003) Galantamine population pharmacokinetics in patients with Alzheimer’s disease: modeling and simulation. J Clin Pharmacol 43:514–523

    Article  CAS  PubMed  Google Scholar 

  37. Gobburu JV, Tammara V, Lesko L et al (2001) Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer’s disease. J Clin Pharmacol 41:1082–1090

    Article  CAS  PubMed  Google Scholar 

  38. Hossain M, Jhee SS, Shiovitz T et al (2002) Estimation of the absolute bioavailability of rivastigmine in patients with mild-moderate dementia of the Alzheimer’s type. Clin Pharmacokinet 41:225–234

    Article  CAS  PubMed  Google Scholar 

  39. Holford NH, Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16:143–166

    Article  CAS  PubMed  Google Scholar 

  40. Sramek JJ, Cutler NR (2000) RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer’s disease therapy? Alzheimer’s Dis Assoc Disord 14:216–227

    Article  CAS  Google Scholar 

  41. Weinstock M (1999) Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer’s disease. CNS Drugs 12:307–323

    Article  CAS  Google Scholar 

  42. Chianella C, Gragnaniello D, Maisanio Delser P et al (2011) BCHE and CYP2D6 genetic variation in Alzheimer’s disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol 67:1147–1157

    Article  CAS  PubMed  Google Scholar 

  43. Yang YH, Chen CH, Chou MC et al (2013) Concentration of donepezil to the cognitive response in Alzheimer’s disease. J Clin Psychopharmacol 33:351–355

    Article  PubMed  Google Scholar 

  44. Jann MW (2000) Rivastigmine, a new generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy 20:1–12

    Article  CAS  PubMed  Google Scholar 

  45. Farlow MR, Salloway S, Tariot PN et al (2010) Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther 32:1234–1251

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Christensen DD (2012) Higher dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-severe Alzheimer’s disease. Postgrad Med 124:110–116

    Article  PubMed  Google Scholar 

  47. Okamura N, Funaki Y, Tashiro M et al (2008) In vivo visualization of donepezil binding in the brain of patients with Alzheimer’s disease. Br J Clin Pharmacol 65:472–479

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Shimada A, Hashimoto H, Kawabe J et al (2011) Evaluation of therapeutic response to donepezil by positron emission tomography. Osaka City Med J 57:11–19

    CAS  PubMed  Google Scholar 

  49. Kasuya M, Meguro K, Okamura N et al (2012) Greater responsiveness to donepezil in Alzheimer’s patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study. Alzheimer’s Dis Assoc Disord 26:113–118

    Article  CAS  Google Scholar 

  50. Potkin S, Anand R, Fleming K et al (2001) Brain metabolic and clinical effects of rivastigmine in Alzheimer’s disease. Int J Neuropsychopharmacol 4:223–230

    Article  CAS  PubMed  Google Scholar 

  51. Stefanova E, Wall A, Almkvist O et al (2006) Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease. J Neural Transm 113:205–218

    Article  CAS  PubMed  Google Scholar 

  52. Kadir A, Darreh-Shori T, Almkvist O et al (2007) Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET. Psychopharmacology 191:1005–1014

    Article  CAS  PubMed  Google Scholar 

  53. Mega MS, Dinov ID, Porter V et al (2005) Metabolic patterns associated with the clinical response to galantamine therapy. Arch Neurol 62:721–728

    Article  PubMed  Google Scholar 

  54. Darreh-Shori T, Kadir A, Almkvist O et al (2008) Inhibition of acetylcholinesterase in CS versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging 29:168–184

    Article  CAS  PubMed  Google Scholar 

  55. Kadir A, Darreh-Shori T, Almkvist O et al (2008) PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 29:1204–1217

    Article  CAS  PubMed  Google Scholar 

  56. McKeage K (2009) Memantine: a review of its use in moderate to severe Alzheimer’s disease. CNS Drugs 23:881–897

    Article  CAS  PubMed  Google Scholar 

  57. Atri A, Hendrix SB, Pejovic V et al (2015) Cumulative, additive benefits of memantine-donepezil combination component monotherapies in moderate-to-severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers Res Ther 7(1):28. doi:10.1186/s13195-015-0109-2

    Article  PubMed  PubMed Central  Google Scholar 

  58. Kornhuber J, Kennepohl EM, Bleich S et al (2001) Memantine pharmacotherapy. Clin Pharmacokinet 46:599–612

    Article  Google Scholar 

  59. Periclou A, Ventura D, Rao N, Abramowitz W (2006) Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 79:134–143

    Article  CAS  PubMed  Google Scholar 

  60. Moritoyo T, Hasunuma T, Harada K et al (2012) Effect of renal impairment on the pharmacokinetics of memantine. J Pharmacol Sci 119:324–329

    Article  CAS  PubMed  Google Scholar 

  61. Noetzli M, Guidi M, Ebbing K et al (2013) Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin Pharmacokinet 52:211–223

    Article  CAS  PubMed  Google Scholar 

  62. Gomolin IH, Smith C, Jietner TM (2010) Once-daily memantine pharmacokinetic and clinical considerations. JAGS 58:1812–1813

    Article  Google Scholar 

  63. Lam S, Smith C, Gomolin IH (2015) Memantine standard tablet and extended-release dosing considerations: a pharmacokinetic analysis. JAGS 63:183–184

    Article  Google Scholar 

  64. Kornhuber J, Quack G (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195:137–139

    Article  CAS  PubMed  Google Scholar 

  65. Jones RW, Bayer A, Inglis F, Barkers A, Phul R (2007) Safety and tolerability on once-daily versus twice-daily memantine: a randomized, double-blind study in moderate to severe Alzheimer’s disease. Int J Geriatr Psychiatry 22:258–262

    Article  PubMed  Google Scholar 

  66. Grossberg GT, Manes F, Allegri RF et al (2013) The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs 27:469–478

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Ametamey SM, Bruehlmeier M, Kneifel S et al (2002) PET studies of 18F-memantine in healthy volunteers. Nucl Med Biol 29:227–231

    Article  CAS  PubMed  Google Scholar 

  68. Chow TW, Graff-Guerrero A, Verhoeff NP et al (2011) Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatr Dis Treat 7:415–424

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Chow TW, Farm D, Graff-Guerrero A et al (2013) FDG-PET in semantic dementia after 6 months of memantine: an open-label study. Int J Geriatr Psychiatry 28:319–325

    Article  PubMed  PubMed Central  Google Scholar 

  70. Sultzer DL, Melrose RJ, Harwood DG, Campa O, Mandelkern MA (2010) Effects of memantine treatment on regional cortical metabolism in Alzheimer’s disease. Am J Geriatr Psychiatry 18:606–614

    Article  PubMed  Google Scholar 

  71. Wang T, Huang Q, Reiman EM et al (2013) Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer’s dementia. J Clin Psychopharmacol 33:636–642

    Article  PubMed  Google Scholar 

  72. Prvulovic D, Schneider B (2014) Pharmacokinetic and pharmacodynamics evaluation of donepezil for the treatment of Alzheimer’s disease. Expert Opin Drug Metab Toxicol 10:1039–1050

    Article  CAS  PubMed  Google Scholar 

  73. Small GW, Bullock R (2011) Defining optimal treatment with cholinesterase inhibitors in Alzheimer’s disease. Alzheimer’s Demen 7:177–184

    Article  CAS  Google Scholar 

  74. Zhong Y, Zheng X, Miao Y et al (2013) Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease. Am J Med Sci 34:222–226

    Article  Google Scholar 

  75. Noetzli M, Guidi M, Ebbing K et al (2013) Relationship of CYP2D6, CYP3A, POR, ABCB1, genotypes with galantamine steady-state plasma concentrations. Ther Drug Monit 35:270–275

    Article  CAS  PubMed  Google Scholar 

  76. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR (2002) Inhibition of acetyl – and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 109:1053–1065

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Healthcare Innovation, Midwestern University, Glendale, AZ, USA

    Chad M. VanDenBerg PharmD

  2. Department of Pharmacotherapy, University of North Texas System College of Pharmacy (UNTSCP) and University of North Texas Health Science Center (UNTHSC), Fort Worth, TX, USA

    Michael W. Jann PharmD

Authors
  1. Chad M. VanDenBerg PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael W. Jann PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael W. Jann PharmD .

Editor information

Editors and Affiliations

  1. Univ. North Texas Sys, Col Pharmacy, Department of Pharmacotherapy, FORT WORTH, Texas, USA

    Michael W. Jann

  2. Department of Pharmacotherapy, Univ. North Texas Sys, Col Pharm, FORT WORTH, Texas, USA

    Scott R. Penzak

  3. Department of Pharmacotherapy, Univ. North Texas Sys, Col Pharm., FORT WORTH, Texas, USA

    Lawrence J. Cohen

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

VanDenBerg, C.M., Jann, M.W. (2016). Antidementia Drugs. In: Jann, M., Penzak, S., Cohen, L. (eds) Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Adis, Cham. https://doi.org/10.1007/978-3-319-27883-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27883-4_13

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-27881-0

  • Online ISBN: 978-3-319-27883-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation